文献速递乳腺MR

极密乳腺女性补充MRI筛查第二轮DENSE试验结果

Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial.
PubMed 文献 · Radiology · 2021-03-16

DENSE试验第二轮(发病轮)纳入3436名极密乳腺女性,在首次MRI两年后再次行补充MRI筛查。癌检出率为5.8/1000次筛查(95%CI 3.8, 9.0),低于第一轮的16.5/1000次筛查(95%CI 13.3, 20.5);假阳性率为26.3/1000次筛查(95%CI 21.5, 32.3),低于第一轮的79.8/1000次筛查(95%CI 72.4, 87.9)。第二轮所有肿瘤均为0-I期且淋巴结阴性。

要点

  • 第二轮补充MRI癌检出率5.8/1000次筛查,第一轮为16.5/1000次筛查。
  • 第二轮假阳性率26.3/1000次筛查,较第一轮79.8/1000次筛查明显降低。
  • 第二轮所有检出肿瘤均为0-I期且淋巴结阴性。

关键影像表现/征象

  • 第二轮所有检出肿瘤均为0-I期且淋巴结阴性。

诊断标准与关键数值

  • 第二轮癌检出率为5.8/1000次筛查(95%CI 3.8, 9.0),第一轮为16.5/1000次筛查(95%CI 13.3, 20.5)。
  • 第二轮假阳性率为26.3/1000次筛查(95%CI 21.5, 32.3),第一轮为79.8/1000次筛查(95%CI 72.4, 87.9)。
  • 第二轮召回阳性预测值为18%(20/110名被召回参与者;95%CI 12.1, 26.4),与第一轮相当。
  • 第二轮活检阳性预测值为24%(20/84名接受活检参与者;95%CI 16.0, 33.9),与第一轮相当。

临床应用与阅片要点

  • 第二轮补充MRI癌检出率为5.8/1000次筛查,低于第一轮的16.5/1000次筛查。
  • 第二轮假阳性率为26.3/1000次筛查,低于第一轮的79.8/1000次筛查。
  • 第二轮召回阳性预测值为18%(20/110),活检阳性预测值为24%(20/84)。
  • 第二轮所有检出肿瘤均为0-I期且淋巴结阴性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background In the first (prevalent) supplemental MRI screening round of the Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial, a considerable number of breast cancers were found at the cost of an increased false-positive rate (FPR). In incident screening rounds, a lower cancer detection rate (CDR) is expected due to a smaller pool of prevalent cancers, and a reduced FPR, due to the availability of prior MRI examinations. Purpose To investigate screening performance indicators of the second round (incidence round) of the DENSE trial. Materials and Methods The DENSE trial (ClinicalTrials.gov: NCT01315015) is embedded within the Dutch population-based biennial mammography screening program for women aged 50-75 years. MRI examinations were performed between December 2011 and January 2016. Women were eligible for the second round when they again had a negative screening mammogram 2 years after their first MRI. The recall rate, biopsy rate, CDR, FPR, positive predictive values, and distributions of tumor characteristics were calculated and compared with results of the first round using 95% CIs and χ2 tests. Results A total of 3436 women (median age, 56 years; interquartile range, 48-64 years) underwent a second MRI screening. The CDR was 5.8 per 1000 screening examinations (95% CI: 3.8, 9.0) compared with 16.5 per 1000 screening examinations (95% CI: 13.3, 20.5) in the first round. The FPR was 26.3 per 1000 screening examinations (95% CI: 21.5, 32.3) in the second round versus 79.8 per 1000 screening examinations (95% CI: 72.4, 87.9) in the first round. The positive predictive value for recall was 18% (20 of 110 participants recalled; 95% CI: 12.1, 26.4), and the positive predictive value for biopsy was 24% (20 of 84 participants who underwent biopsy; 95% CI: 16.0, 33.9), both comparable to that of the first round. All tumors in the second round were stage 0-I and node negative. Conclusion The incremental cancer detection rate in the second round was 5.8 per 1000 screening examinations-compared with 16.5 per 1000 screening examinations in the first round. This was accompanied by a strong reduction in the number of false-positive results. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Moy and Gao in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Veenhuizen SGA, de Lange SV, Bakker MF, et al. Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology. 2021. PMID: 33724062. doi:10.1148/radiol.2021203633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。